Mobile Platform in the Workplace: The Next Generation Practice in Human Resource

AbstractThis research paper uncovers the practice and challenges of implementing mobile platform in the workplace. The key contribution of this research study will enlighten business community to be open to the use of this platform in order to transmit data and information that is vital for the organization. These transform both business and education in the next level which serve as a challenge for organizational development. This platform will continue to shape our business and education system as the next generation of tools for learning and development. In fact using this platform will provide foundation for efficient and effective organization

“Un trattato che nega il dubbio e lʼinfedeltà dai cristiani monoteisti” attrubuito a Buṭrus al-Sadamantī Introduzione, traduzione e nota comparativa

Butrus era un monaco e sacerdote, ed era considerato un uomo santo.  La sola data conosciuta della sua vita è il 1260, quando scrisse un’opera dedicata al suo ex confratello nel monastero, Yusab vescovo di Akhmim.Nell’ unico manoscritto conosciuto questo trattato è anonimo, quindi vi debbono essere alcune riserve circa la sua attribuzione a Butrus. Va anche notato che, mentre gli stessi argomenti sono nel Trattato della credenza, i termini usati sono diversi. Lʼintenzione del trattato è chiaramente apologetico: vi si tratta della Trinità e della divinità di Cristo, le due dottrine oggetto di maggiori indagini da parte dei Musulmani.

“A Treaty that Denies Doubt and Infidelity of Monotheistic Christians” Attributed to Buṭrus alSadamantī. Introduction, Translation and a Comparative Note

L’articolo presente la prima traduzione di un testo apologetico cristiano in arabo. L’apologia è conservata in un unico copto-arabo manoscritto, Vat. ar. 126, 239r-241r, e contiene testo composito riguardante la difesa della dottrina della Trinità e dell’incarnazione contro le accuse dei muslumani. La parte trinitaria è una versione della confessione di fede di Elia di Nisibi (975-1046). Il paragone della parte cristologica del testo con la liturgia copta di san Basilio mostra che il testo perde il suo carattere apologetico e assume un tono più declarativo e confessionale. Il testo è stato attribuito al monaco copto Buṭrus alSadamantī che ha vissuto nella seconda meta del XIII secolo, però la composizione del testo mette in dubbio la sua autenticità.The article presents the first translation of a Christian apologetic text in Arabic. The apology is conserved in a single copto-arabic manuscript, Vat. ar. 126, 239r-241r, and contains a composite text concerning the defense of the doctrine of the Trinity and of the incarnation against the accusations of Muslims. The Trinitarian part is a version of the confession of faith of Elias of Nisibis (975-1046). However, the comparison of the Christological part of the text with the Coptic liturgy of St. Basil shows that the text loses its clear apologetic character and assumes a declarative and confessional tone. The text was attributed to the Coptic monk Buṭrus al-Sadamantī who lived in the second half of the thirteenth century but the composition of the text casts doubts on its authenticity

Performance Evaluation of a Prestressed Belitic Calcium Sulfoaluminate Cement (BCSA) Concrete Bridge Girder

Belitic calcium sulfoaluminate (BCSA) cement is a sustainable alternative to Portland cement that offers rapid setting characteristics that could accelerate throughput in precast concrete operations. BCSA cements have lower carbon footprint, embodied energy, and natural resource consumption than Portland cement. However, these benefits are not often utilized in structural members due to lack of specifications and perceived logistical challenges. This paper evaluates the performance of a full-scale precast, prestressed voided deck slab bridge girder made with BCSA cement concrete. The rapid-set properties of BCSA cement allowed the initial concrete compressive strength to reach the required 4300 psi release strength at 6.5 h after casting. Prestress losses were monitored long-term using vibrating wire strain gages cast into the concrete at the level of the prestressing strands and the data were compared to the American Association of State Highway and Transportation Officials Load and Resistance Factor Design (AASHTO LRFD) predicted prestress losses. AASHTO methods for prestress loss calculation were overestimated compared to the vibrating wire strain gage data. Material testing was performed to quantify material properties including compressive strength, tensile strength, static and dynamic elastic modulus, creep, and drying and autogenous shrinkage. The material testing results were compared to AASHTO predictions for creep and shrinkage losses. The bridge girder was tested at mid-span and at a distance of 1.25 times the depth of the beam (1.25d) from the face of the support until failure. Mid-span testing consisted of a crack reopening test to solve for the effective prestress in the girder and a flexural test until failure. The crack reopen effective prestress was compared to the AASHTO prediction and AASHTO appeared to be effective in predicting losses based on the crack reopen data. The mid-span failure was a shear failure, well predicted by AASHTO LRFD. The 1.25d test resulted in a bond failure, but nearly developed based on a moment curvature estimate indicating the AASHTO bond model was conservative

The semi-annual thermospheric density variation between 200 - 560 km

Fourier analysis is used to find the semi-annual variation of the thermospheric total density; the variation is characterized by a "Density index D". The results of the individual annual runs were subjected to statistical treatment and a formula for the semi-annual variation was found. It is then compared to the formula used in the CIRA 72 model

Clinical and microbiological outcomes of ceftazidime-avibactam treatment in adults with Gram-negative bacteremia: A subset analysis from the phase 3 clinical trial program

INTRODUCTION: This exploratory analysis assessed efficacy and safety outcomes in patients with Gram-negative bacteremia treated with ceftazidime-avibactam or comparator across five phase 3, randomized, controlled, multi-center trials in adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI)/pyelonephritis, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). METHODS: In each trial, RECLAIM and RECLAIM 3 (cIAI; NCT01499290/NCT01726023), REPRISE (cIAI/cUTI; NCT01644643), RECAPTURE (cUTI; NCT01595438/NCT01599806), and REPROVE (HAP/VAP; NCT01808092), patients were randomized 1:1 to intravenous ceftazidime-avibactam (plus metronidazole for those with cIAI) or comparators (carbapenems in \u3e 97% patients) for 5-21 days. Efficacy assessments included clinical and microbiological responses at the test-of-cure visit in the pooled Gram-negative extended microbiologically evaluable (GNeME) population (bacteremia subset). Safety outcomes were summarized for patients with positive bacterial blood culture(s) at baseline who received ≥ 1 dose of study treatment. RESULTS: The overall safety population included 4050 patients (ceftazidime-avibactam, n = 2024; comparator, n = 2026). The GNeME population (bacteremia subset) comprised 101 patients (ceftazidime-avibactam, n = 54; comparator, n = 47). Clinical cure rates (all indications combined) were 47/54 (87.0%) for ceftazidime-avibactam and 39/47 (83.0%) for comparators; favorable microbiological response rates were 43/54 (79.6%) and 32/47 (68.1%), respectively. Clinical and microbiological responses in the bacteremia subset were generally similar to those in the overall set. The pattern of adverse events in patients with bacteremia was similar between treatment groups and was consistent with the known safety profile of ceftazidime-avibactam. CONCLUSION: This analysis provides supportive evidence of the efficacy and safety of ceftazidime-avibactam in patients with Gram-negative bacteremia associated with cIAI, cUTI/pyelonephritis, or HAP/VAP

Clinical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with candidemia caused by Candida auris : results from a Phase 2 trial

DATA AVAILABILITY: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris. Eligible participants were ≥18 years, with established candidemia and/or invasive candidiasis caused by C. auris, (cultured within 120 h [for candidemia] or 168 h [for invasive candidiasis without candidemia] with accompanying clinical signs) and limited treatment options. Participants were treated with FMGX (≤42 days; loading dose: 1000 mg IV twice daily [Day 1], followed by 600 mg IV once daily [QD]). Switching to oral FMGX 800 mg QD was permitted from Day 4. Primary endpoint was treatment success (survival and clearance of C. auris from blood/tissue cultures without additional antifungals) at the end of the study treatment (EOST), assessed by an independent data review committee (DRC). Day 30 survival was a secondary endpoint. In vitro susceptibility of Candida isolates was assessed. Nine participants with candidemia (male:6, female:3; 21 to 76 years) in intensive care units in South Africa were enrolled; all received IV FMGX only. DRC-assessed treatment success at EOST and Day 30 survival were 89% (8/9). No treatment related adverse events or study drug discontinuations were reported. FMGX demonstrated potent in vitro activity against all C. auris isolates (MIC range: 0.008 to 0.015 μg/mL [CLSI]; 0.004–0.03 μg/mL [EUCAST]), with the lowest MICs compared to other antifungals tested. Thus, the results showed that FMGX was safe, well-tolerated, and efficacious in participants with candidemia caused by C. auris.Amplyx, a subsidiary of Pfizer Inc.https://journals.asm.org/journal/aacCritical Car